Noortje G Rossen1, Susana Fuentes2, Kirsten Boonstra3, Geert R D'Haens3, Hans G Heilig2, Erwin G Zoetendal2, Willem M de Vos4, Cyriel Y Ponsioen1. 1. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands c.y.ponsioen@amc.uva.nl. 2. Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands. 3. Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands. 4. Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands Departments of Bacteriology & Immunology and Veterinary Biosciences, University of Helsinki, Finland.
Abstract
BACKGROUND: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that is strongly associated with a particular phenotype of inflammatory bowel disease (IBD) with right-sided colonic involvement. In IBD, several studies demonstrated significant aberrancies in the intestinal microbiota in comparison with healthy controls. We aimed to explore the link between IBD and PSC by studying the intestinal mucosa-adherent microbiota in PSC and ulcerative colitis (UC) patients and noninflammatory controls. METHODS: We included 12 PSC patients, 11 UC patients, and nine noninflammatory controls. The microbiota composition was determined in ileocecal biopsies from each patient by 16S rRNA-based analyses using the human intestinal tract chip. RESULTS: Profiling of the mucosa-adherent microbiota of PSC patients, UC patients, and noninflammatory controls revealed that these groups did not cluster separately based on microbiota composition. At the genus-like level, the relative abundance of uncultured Clostridiales II was significantly lower (almost 2-fold) in PSC (0.26 ± 0.10%) compared with UC (0.41 ± 0.29%) and controls (0.49 ± 0.25%) (p = 0.02). Diversity and richness in the microbiota composition differed across the groups and were significantly lower in PSC patients compared with noninflammatory controls (p = 0.04 and p = 0.02, respectively). No significant differences were found in evenness. CONCLUSIONS: Reduced amounts of uncultured Clostridiales II in PSC biopsies in comparison with UC and healthy controls can be considered a signature of a compromised gut, as we have recently observed that this group of as yet uncultured Firmicutes correlates significantly with health.
BACKGROUND:Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that is strongly associated with a particular phenotype of inflammatory bowel disease (IBD) with right-sided colonic involvement. In IBD, several studies demonstrated significant aberrancies in the intestinal microbiota in comparison with healthy controls. We aimed to explore the link between IBD and PSC by studying the intestinal mucosa-adherent microbiota in PSC and ulcerative colitis (UC) patients and noninflammatory controls. METHODS: We included 12 PSC patients, 11 UC patients, and nine noninflammatory controls. The microbiota composition was determined in ileocecal biopsies from each patient by 16S rRNA-based analyses using the human intestinal tract chip. RESULTS: Profiling of the mucosa-adherent microbiota of PSC patients, UC patients, and noninflammatory controls revealed that these groups did not cluster separately based on microbiota composition. At the genus-like level, the relative abundance of uncultured Clostridiales II was significantly lower (almost 2-fold) in PSC (0.26 ± 0.10%) compared with UC (0.41 ± 0.29%) and controls (0.49 ± 0.25%) (p = 0.02). Diversity and richness in the microbiota composition differed across the groups and were significantly lower in PSC patients compared with noninflammatory controls (p = 0.04 and p = 0.02, respectively). No significant differences were found in evenness. CONCLUSIONS: Reduced amounts of uncultured Clostridiales II in PSC biopsies in comparison with UC and healthy controls can be considered a signature of a compromised gut, as we have recently observed that this group of as yet uncultured Firmicutes correlates significantly with health.
Authors: Bill Vestergaard; Łukasz Krych; Leif R Lund; Bettina P Jørgensen; Lars Hansen; Henrik E Jensen; Dennis S Nielsen; Axel K Hansen Journal: Comp Med Date: 2015-10 Impact factor: 0.982
Authors: J Torres; X Bao; A Goel; J-F Colombel; J Pekow; B Jabri; K M Williams; A Castillo; J A Odin; K Meckel; F Fasihuddin; I Peter; S Itzkowitz; J Hu Journal: Aliment Pharmacol Ther Date: 2016-02-09 Impact factor: 8.171
Authors: D Kevans; A D Tyler; K Holm; K K Jørgensen; M H Vatn; T H Karlsen; G G Kaplan; B Eksteen; D Gevers; J R Hov; M S Silverberg Journal: J Crohns Colitis Date: 2015-11-02 Impact factor: 9.071